TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06615505

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: VIA Disc NP
Description: Participants will receive a single dose, intradiscal injection of 100 mg of VIA Disc NP mixed with sterile saline according to product Instructions for Use (IFU) and administered to the affected level(s), L1-S1 (1 or 2 levels).

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Injection
Description: Participants will receive the sham procedure at 1 or 2 levels.~The procedure will be identical to the investigational procedure with the following exception: A 20G spinal needle will be carefully inserted through the skin and muscle of the back but WILL NOT penetrate the annulus fibrosus of the intervertebral disc.
Study: NCT05039632

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hafnium Oxide-containing Nanoparticles NBTXR3
Description: Given intratumorally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hafnium Oxide-containing Nanoparticles NBTXR3
Description: Given intratumorally

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo Abscopal radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo RadScopal radiation therapy
Study: NCT06609369

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental health intervention
Description: Behavioral health intervention

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: Days 1-3: 0.5mg once daily, Days 4-7: 0.5mg twice daily; Days 8-56: 1.0mg twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: Days 1-3: 0.5mg once daily, Days 4-7: 0.5mg twice daily; Days 8-56: 1.0mg twice daily.
Study: NCT06671015

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Airvo 3
Description: Provides effective therapy for acute hypoxemic respiratory failure and post-extubation respiratory support for 24 hours post-extubation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Airvo 3
Description: Provides effective therapy for acute hypoxemic respiratory failure and post-extubation respiratory support for 24 hours post-extubation.
Study: NCT06613126

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Symptom Management APP group
Description: Based on symptom management theory and the relevant literature, the researcher designed a symptom management APP. The APP includes a symptom recording system, symptom management skills, and Tourette Syndrome knowledge information to facilitate parents' and children's joint learning.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: health education instructions group
Description: To receive outpatient verbal and paper health education guidance from healthcare providers.
Study: NCT06669949

Intervention type: OTHER
Intervention: no intervention
Description: No interventions are involved in this observational study.

Intervention type: OTHER
Intervention: no intervention
Description: No interventions are involved in this observational study.

Intervention type: OTHER
Intervention: no intervention
Description: No interventions are involved in this observational study.
Study: NCT05799872

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Affect Treatment for Anorexia Nervosa (PAT-AN):
Description: PAT-AN is an adaptation of the cognitive-behavioral outpatient individual therapy for anhedonia (17, 68). The overarching aim of PAT-AN is to enhance reward sensitivity (reward anticipation, experiencing, and learning) to non-eating disorder experiences and to decrease or replace reward sensitivity to weight-loss experiences (26). PAT-AN includes 6 sequential modules, each designated to target specific reward sensitivity disturbances (26, 68). Homework and experiential practice during sessions are essential components of PAT-AN, and participants are provided a workbook to assist with this practice. During each session, collaborative homework review is followed by skill development and homework assignments.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducational and Behavioral Therapy (PBT)
Description: The comparison treatment is modeled off of educational and behavioral interventions used in prior clinical trials for AN and common elements of standard behavioral eating disorder treatments. The treatment is structured to parallel the modular format of PAT-AN.
Study: NCT06291155

Intervention type: DRUG
Group type: OTHER
Intervention: SGLT2 inhibitor
Description: All participants will be receive 100 mg/daily doses of Canagliflozin (INVOKANA) for 6 months. Canagliflozin is a Sodium-glucose cotransporter 2 (SGLT2) inhibitor
Study: NCT06621966

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Olive Oil Topical Oil
Description: The IVG will receive standard PI prevention care along with a topical application of olive oil for 7 consecutive days. PI point prevalence and baseline risk assessments will be performed prior to the intervention. Post-intervention assessments will be conducted from days 3 to 8. Descriptive statistics and paired sample t-tests will be utilized for data analysis.
Study: NCT06625827

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nemtabrutinib
Description: Oral administration
Study: NCT06624462

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment in the Meta Care Clinic
Description: * Consultations by medical doctors with specific metabolic training from the metabolic clinic located at Centre for Addiction and Mental Health in Toronto, Canada, and an exercise physiologist.~* Evaluation of their psychopharmacotherapy with consultation and detailed recommendations to the patients' treating psychiatrist and/or general practitioner regarding dosage reductions or switching of psychotropics if this is clinically feasible to reduce the metabolic burden.~* Lifestyle interventions~* Pharmacotherapy with evidence to support use to mitigate antipsychotic-induced weight gain~* Treatment of other cardiovascular risk factors such as dyslipidaemia, hypertension, smoking and diabetes in close collaboration with recognized specialists in endocrinology.~* Assessment of plans at conferences with participation of the sponsor, the primary investigator as well as recognized specialists in endocrinology and psychiatry.~* Qualitative interviews will be conducted post-intervention.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care with general practitioner and/or outpatient clinics
Description: Following measurements after 12 months, patients will receive individualized lifestyle recommendations from an exercise physiologist and a MD will offer to send recommendations regarding the following potential post-trial interventions to the patient's general practitioner and/or outpatient clinic prepared in close collaboration with recognized specialists in psychiatry and endocrinology:~* Suggestions regarding relevant psychotropic medication adjustments or switches if this is found relevant and clinically feasible to reduce the metabolic burden.~* Suggestions regarding potential add-on of weight reducing pharmacotherapy.~* Suggestions regarding pharmacological treatment of other cardiovascular risk factors such as dyslipidaemia, hypertension, smoking and type 2 diabetes.
Study: NCT06625801

Intervention type: DEVICE
Intervention: IVUS
Description: Intravascular Ultrasound
Study: NCT06625541

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AJ302-IM
Description: 7 cohorts (7 dose levels) of participants are planned to be dosed.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study: NCT06625125

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention
Description: The mindful mediators are asked to act as neutral observers who quietly attend to, notice, and let go of internal and external stimuli (present experiences) such as thoughts, feelings, physical sensations, and sounds without reactions, evaluation, and judgments. (Smith, 2005).~The subjects in the mindfulness-based intervention (MBI) group will receive 30 minutes individually administered, guided, chairside interventions during their hemodialysis sessions, three times a week over eight weeks (Alhawatmeh et al., 2022; Thomas et al., 2017). Subjects in this group will receive their assigned intervention developed by the principal investigator (PI) according to the Smith's MBI protocol that will provide intervention instructions. During the eight weeks and at bedtime at night, the subjects will be optionally encouraged to practice the intervention at home.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Progressive muscle relaxation
Description: he progressive muscle relaxation (PMR) group will receive the ABC version of PMR (Smith, 2005). This abbreviated version of PMR involves a tense-let go exercise of 11 muscle groups including hand, arm, arm and sides, back, shoulder, face, front of neck, stomach, chest, leg, and foot.~As the MBI group, the subjects in the PMR group will receive 30 minutes individually administered, guided, chairside interventions during their hemodialysis sessions, three times a week over eight weeks. Subjects in this group will receive their assigned intervention developed by the principal investigator (PI) according to the Smith's PMR protocol that will provide intervention instructions. During the eight weeks and at bedtime at night, the subjects will be optionally encouraged to practice the intervention at home.
Study: NCT06309238

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive weight loss intervention
Description: Intensive weight loss intervention, incl. total meal replacements, behavioural support, and weight loss medication

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bariatric surgery
Description: Roux-en-Y Gastric Bypass (RYGB) or Sleeve Gastrectomy (SG)
Study: NCT06245603

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hydeal Cyst®
Description: BCG or MMC will be started within 1-2 weeks from randomization (within 4-6 weeks after TURB).~BCG or MMC will be administered once a week by intravesical instillation: BCG will be abministered for 6 weeks and MMC for 8 weeks. (induction cycles) Before instillations a physical examination will be performed and symptoms evaluated: changes from baseline and abnormalities will be recorded in patient notes.~IPSS questionnaire and QoL questionaire will be administered to the patient at week 1, 4 and 6/8 (6 for BCG and 8 for MMC) of treatment.~48 hours after post BCG or MMC intravesical instillation, patients of Arm A will undergo Hydeal Cyst intravesical instillation.~BCG patiens will received 6 Hydeal Cyst intravesical instillation; MMC patiens will received 8 Hydeal Cyst intravesical instillation.
Study: NCT06624423

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: corn silk tea
Description: Corn Silk Tea

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: corn silk tea
Description: Corn Silk Tea
Study: NCT06624865

Intervention type: OTHER
Intervention: Blood and stool sampling
Description: Blood and stool sampling
Study: NCT06624917

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Green Breast Surgery Protocol
Description: A perioperative protocol aiming at reducing environmental impact of surgery, and fast recovery protocol to reduce hospitalization.
Study: NCT06625294

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Task -oriented training with bilateral functional task training exercises
Description: Task oriented training approach with BFTT will consists of different tasks including:~Hand Movements:~1. Fold a small cloth towel with both hands with initially putting the towel flat on the table and gradually folding it into a large towel roll.~2. Put a small amount of putty on patient's table and instruct to roll it with the help of rolling pin moving it back and forth using both the hands.~3. Place a jar with a removable lid on the table and instruct the patient to remove lid from the jar completely by holding the jar with either hand and remove the lid with the alternate hand.~4. Pouring water: Pour water from jug while holding the jug in unaffected hand to cup/glass that is held in affected hand and activity can be done the other way round as well.~5. Pour water from one hard plastic cup to another while alternatively involving both the hands (we must not allow deformation of the cup)~6. Plunging action with coffee maker against water resistance:Fill the coffee maker with water.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Task Oriented Training with CIMT
Description: • Hand Movements:~1. Sitting at a table (Wrist Extension): Affected forearm resting on table. Place cylindrical object in palm of patient's hand. Patient asked to move the hand towards the forearm (dorsiflexion) by extending the wrist - no elbow flexion allowed.~2. Sitting at a table (Radial Deviation of Wrist): Therapist should place forearm with ulnar side on table in mid-pronation / supination position. Thumb in line with forearm and wrist in extension. Fingers around cylindrical object. Patient is asked to lift hand off table. No wrist flexion or extension.~Advanced Hand Activities:~1. Have the patient reach forward to pick up the top of a pen with their affected hand, bring the affected arm back to their side and put the pen cap down in front of them.~2. Place (beans), in a teacup an arm's length away on the affected side. Place another teacup an arm's length away on the intact side. Have the patient pick up one beans with their affected hand and place the beans in the cup on the
Study: NCT06624566

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: Implementation of an intensive therapeutic group exercise program in the neurorehabilitation process
Description: The variables will be measured prior to group assignment The age and sex variables and the satisfaction survey will be measured at the beginning of the program, the other variables at 20 sessions, at 40 sessions, at 60 sessions and/or at hospital discharge. Before the patient starts the program, he/she is classified in group A -patients who have seated trunk control for at least 2 minutes (with supervision) and no standing control (Item 3.3, Berg scale)- or in group B -patients who have standing trunk control for 2 minutes (with supervision) (Item 2.3 on the Berg scale)-. There is a maximum of 4 patients per group with 1 physiotherapist per group.~The difference with respect to the usual treatment of the neurorehabilitation service of the HMS is that in the EINTER program, strength and endurance exercises will be implemented in addition to the usual care plan. The sessions in the EINTER program will be carried out in groups of 4 people with similar functional capacities.
Study: NCT06630858

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Subcostal Anterior Quadratus Lumborum Block
Description: S-QLB3 block will be performed 30 min. before general anesthesia. For anterior QL block via subcostal approach, 0.4 ml/kg of 0.25% bupivacaine + 1:400.000 adrenaline will be injected into the interfacial plane between the QLM and PMM.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intrathecal Morphine
Description: Intrathecal morphine will be performed (a total of 0.2 mg of morphine sulfate + 7.5 mg isobaric bupivacaine).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Patient Controlled Analgesia (IV PCA)
Description: IV morphine-PCA will be applied postoperatively for 24 hours . IV-PCA: The requested dose will be 1mg morphine, the lock-in time will be 6 minutes, the 4-hour limit will be 20 mg morphine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Patient Controlled Analgesia (IV PCA)
Description: IV morphine-PCA will be applied postoperatively for 24 hours . IV-PCA: The requested dose will be 1mg morphine, the lock-in time will be 6 minutes, the 4-hour limit will be 20 mg morphine.
Study: NCT06700460

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laser-assisted in Situ Keratomileusis
Description: LASIK

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implantable Collamer Lens placement
Description: EVO ICL
Study: NCT06695767

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neurobehavioral therapy
Description: Participants will receive an introduction session and 12 1-hour long online sessions once per week for a total of 12 weeks that are guided by the investigator who is trained in NBT.Participants will engage in tools to aid in assuming control over their seizures; contextualize their environment; identify moods, situations, and thoughts; train healthy communication and support seeking; understand central nervous system medications and seizures; conduct a functional behavioral analysis; learn relaxation techniques; examine external stressors and internal triggers; and prepare for life after the intervention. Participants will be asked to complete weekly homework, thought records, seizure logs that are found in their workbooks and to engage in journal entries.
Study: NCT06718803

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypnosis
Description: The Evia program includes three mayor components, 1. A hypnotherapy program for the reduction of hot flashes, 2. Educational readings on hot flashes and menopausal-related topics, 3. Daily hot flash tracker.~The hypnotherapy is delivered in short, daily 10-20 minute audio recordings that involve numerous suggestions for coolness and relaxation (i.e., cool breeze, snowy mountain, deep lake) for a period of five weeks. The hypnotherapy program is based on previous randomized controlled trials for the reduction of hot flashes (Elkins et al., 2008; Elkins et al., 2013).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Structured Attention
Description: Data collection of hot flash severity and frequency will mirror the hot flashes daily tracker offered by the intervention group (Evia app), and account for time and structured attention control while removing any potential therapeutic effects.
Study: NCT06705088

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SUVN-I6107
Description: SUVN-I6107 Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SUVN-I6107
Description: SUVN-I6107 Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: A look-alike tablet with no active ingredient.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: A look-alike tablet with no active ingredient.
Study: NCT06709196

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pivmecillinam
Description: Orally administered pivmecillinam 400mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pivmecillinam
Description: Orally administered targeted antimicrobial prophylaxis based on a urine culture.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin clavulanic acid
Description: Orally administered targeted antimicrobial prophylaxis based on a urine culture.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: Orally administered targeted antimicrobial prophylaxis based on a urine culture.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefuroxime
Description: Orally administered targeted antimicrobial prophylaxis based on a urine culture.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Description: Orally administered targeted antimicrobial prophylaxis based on a urine culture.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linezolid
Description: Orally administered targeted antimicrobial prophylaxis based on a urine culture.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrofurantoin
Description: Orally administered targeted antimicrobial prophylaxis based on a urine culture.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimethoprim
Description: Orally administered targeted antimicrobial prophylaxis based on a urine culture.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfamethoxazole trimethoprim
Description: Orally administered targeted antimicrobial prophylaxis based on a urine culture.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluconazole
Description: Orally administered targeted antimicrobial prophylaxis based on a urine culture.
Study: NCT06727513

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: A single-operator technique for GlideScope intubation.
Description: A single-operator technique where the senior resident will insert the GlideScope and perform the endotracheal intubation using an angulated stylet.
Study: NCT06341907

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Neoantigen polypeptide vaccine
Description: Completion of polypeptide neoantigen polypeptide vaccine (day 1, 4, 8, 15, 22, 54, and 84)
Study: NCT05408871

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adnectin 18F-BMS-986192 Head and Neck Cancer
Description: Head and Neck Cancer: PET imaging will be performed after initial diagnosis and within 2 weeks of MRI or CT of the neck done as standard of care. MRI will include T1 weighted pre and post gadolinium spin echo, diffusion weighted imaging, and T2 weighted imaging. CT of the head and neck with contrast will be performed per standard clinical protocol. Patients will get one intravenous line and one radial artery line placed prior to imaging and up to 5.5mCi (204MBq) of \[18F\] PDL192 tracer will be administered intravenously, as a bolus, once the patient is positioned on the scanner. 42 PET data will be acquired at single bed position and in list mode for 120 min after the start of tracer administration. Samples will be drawn from radial artery line.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adnectin 18F-BMS-986192 Brain Metastases
Description: Brain Metastases: Recruited patients will undergo standard clinical MRI within 2 weeks prior to PET, including T1 weighted pre- and post-gadolinium spin-echo and gradient-echo imaging, diffusion weighted imaging, susceptibility weighted imaging (2D SWI), T2 weighted imaging, 3D FLAIR, and combined DCE and dynamic susceptibility contrast (DSC) perfusion (DCE perfusion will be performed first, DSC perfusion will utilize T2 spin echo images). DCE perfusion will be processed on syngo Tissue 4D software (Siemens). DSC perfusion will be processed with syngo MR Perfusion Engine (Siemens). Patients will get one intravenous line and one radial artery line placed prior to imaging and up to 5.5mCi (204MBq) of \[18F\] PDL192 tracer will be administered intravenously, as a bolus, once the patient is positioned on the scanner. 42 PET data will be acquired at single bed position and in list mode for 120 min after the start of tracer administration. Samples will be drawn from radial artery line.
Study: NCT05728606

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robot-assisted D2 distal gastrectomy
Description: Robot-assisted D2 distal gastrectomy after 3-Cycle SOX neoadjuvant chemotherapy